Total Revenue

Increased to $211.2M in Q1 2025 (up from almost negligible revenue previously)

Total revenue surged to $211.2M in Q1 2025, driven almost entirely by a $195.4M increase in license revenue and $15.9M in service revenue stemming from the Takeda Agreement, contrasting with the very low revenue in Q1 2024. " " "

Net Loss

Rose from $43.1M in Q1 2024 to $148.5M in Q1 2025 (~244% worsening)

Net loss expanded dramatically due to significantly higher operational expenses—such as increased R&D and administrative costs—to support growth, which overwhelmed revenue gains noted in the current period relative to the substantially lower loss in the previous period. " "

Net Loss Per Share

Deteriorated from -$1.21 in Q1 2024 to $3.66 in Q1 2025

Net loss per share worsened as the amplified overall loss was combined with potential dilution factors, intensifying the negative impact on shareholder returns compared to Q1 2024. " "

R&D Expenses

Increased from $38.3M in Q1 2024 to $48.7M in Q1 2025 (approximately 27% increase)

R&D expenses increased notably as KROS ramped up its investment in innovation and pipeline advancement, reflecting a strategic shift from lower R&D spending in Q1 2024 to support future growth with higher clinical and manufacturing investments. " "

Operating Cash Flow

Reversed from a negative $46.0M in Q4 2024 to a positive $161.2M in Q1 2025

Operating cash flow turned positive to $161.2M in Q1 2025 as a result of strong revenue inflows from the Takeda Agreement and improved working capital management, sharply contrasting with the previous quarter’s negative cash flow. " "

Cash and Cash Equivalents

Increased by about 28.6% to $720.5M

Cash reserves expanded to $720.5M driven by robust operating cash inflows and the influx from the Takeda license deal, significantly enhancing liquidity compared to the prior period. " "

Total Assets

Grew by roughly 27.2% to $784.6M

Total assets increased as a result of augmented cash balances and higher accounts receivable—particularly linked to the Takeda Agreement—indicating a stronger balance sheet compared to the previous period. " "